|MDACC Study No:||2008-0267 (clinicaltrials.gov NCT No: NCT00905034)|
|Title:||Phase II study of methotrexate, vincristine, pegylated L-asparaginase and dexamethasone (MOAD) in acute lymphoblastic leukemia (ALL) salvage and Chronic Myeloid Leukemia (CML) in blast phase|
|Principal Investigator:||Gautam Borthakur|
|Treatment Agent:||Dexamethasone; Methotrexate; PEG-L-Asparaginase; Rituximab; Vincristine|
|Study Description:||This goal of this clinical research study is to learn if the combination of |
methotrexate, pegylated-L-asparaginase, vincristine, and dexamethasone (also
rituximab in some patients) can help to control ALL that has not responded to
previous treatment or has come back after a response or CML.